Israeli digital health startup OutSense has extended its Series A financing round to $2.7 million, following an investment from Longevity Venture Partners, the company announced Monday.
Follow Israel Hayom on Facebook and Twitter
OutSense has developed an optical IoT device that can be attached to any toilet bowl. The device scans the human waste, identifies the optical footprint of the feces and urine components, sends the data for AI cloud-based analysis, and then supplies indications of various diseases at a high proven level of precision. The device currently enables the identification of blood in the stool, which is often a sign of colorectal cancer, an application that has been granted a patent in the US, Japan, Europe, and China.
Longevity will begin piloting OutSense's technology for detecting clinical conditions by analyzing human waste later this year. The funds are being used for product development and preparations for large-scale production, which will be followed up by another round of financing to support the company's commercial activity.
The pilot will run in conjunction with CommuniCare Family of Companies, Longevity's parent company, which operates more than 90 health care facilities in the US. OutSense is also conducting clinical trials in Israel, as well as a pilot in Japan.
OutSense CEO Yfat Scialom noted, "The access to real-use environments that the Longevity's investment brings to the table is invaluable … The pilot tests in the US and Japan, as well as the clinical trials in Israel, are an important milestone toward our plan to launch production and commercial sales which are planned for the first quarter of 2022."
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
